FDA to pursue pharma exec prosecutions; Portal aids cold-chain audits;

> Following GAO criticism of its industry performance-standards development, the FDA says it plans to "thoughtfully" invoke its seldom-used "strict liability" tool to prosecute corporate executives for criminal actions within their companies. Article

> The Kelsius Cold Chain Portal sits atop a SaaS-based wireless sensor network, providing data from various operational points to a repository that can format audit trail documentation. Release

> VGXI has nearly doubled its cGMP plasmid manufacturing facility in Texas to meet demand for our research and manufacturing services. Announcement

> India is claiming title as the world's top exporter of generic medicines. Article

> The FDA has given its thumbs-up to the facility intended for commercial production of Cell Therapeutics' non-Hodgkin's lymphoma treatment pixantrone, expected to undergo FDA review this month. Release

Suggested Articles

Lonza CEO Marc Funk is leaving for "personal reasons" after less than a year in the top job. 

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

Just weeks after selling the sterile manufacturing assets of its Kyowa operation in Japan, it has unloaded the rest of its Kyowa drugmaking operation.